<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862912</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ0916</org_study_id>
    <nct_id>NCT02862912</nct_id>
  </id_info>
  <brief_title>Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)</brief_title>
  <official_title>Chloroprocaine Versus Bupivacaine Spinal Anesthesia for Cervical Cerclage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether or not spinal anesthesia with the local anesthetic drug,
      chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in
      faster discharge from the post-anesthesia care unit after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, randomized, double blind clinical trial. Subjects will be ASA I
      and II women ≥18 yrs old with a singleton pregnancy in the 1st or 2nd trimester of pregnancy
      undergoing cervical cerclage with spinal anesthesia. Patients will be randomly allocated to
      the chloroprocaine (CP) or bupivacaine group (BUP). Patients will receive spinal anesthesia
      with either chloroprocaine 50 mg with fentanyl 15 mcg or bupivacaine 9 mg with fentanyl 15
      mcg.

      Bupivacaine is the most common local anesthetic used for cervical cerclage with spinal
      anesthesia. Bupivacaine is safe and has been preferred over other medications such as
      lidocaine, because it is associated with a low incidence of a complication from spinal
      anesthesia known as &quot;transient neurologic symptoms&quot; - a condition where pain and cramping in
      the buttocks and lower extremities can be experienced for several days. Bupivacaine is a
      long-acting local anesthetic agent and therefore has the disadvantage of a prolonged
      anesthetic recovery that may last a few hours.

      Chloroprocaine is a local anesthetic with a fast onset and short duration that may be used
      for spinal anesthesia for ambulatory procedures. Chloroprocaine is currently used at the
      research institution for spinal anesthesia for ambulatory surgical patients, especially for
      lower extremity orthopedic procedures such as knee arthroscopy, as well as for pregnant
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2016</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of Motor Block</measure>
    <time_frame>3 hours</time_frame>
    <description>The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale:
Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulate</measure>
    <time_frame>5 hours</time_frame>
    <description>Time from spinal anesthesia placement to ability to ambulate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Void</measure>
    <time_frame>5 hours</time_frame>
    <description>Time from spinal anesthesia injection to ability to void spontaneously.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Adverse Reaction to Spinal Anesthetic</condition>
  <condition>Maternal Care for Cervical Incompetence</condition>
  <arm_group>
    <arm_group_label>Chloroprocaine (CP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine (BUP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroprocaine</intervention_name>
    <description>Administered as a single injection or continuously through an indwelling catheter - 50 mg</description>
    <arm_group_label>Chloroprocaine (CP)</arm_group_label>
    <other_name>Nesacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)</description>
    <arm_group_label>Bupivacaine (BUP)</arm_group_label>
    <other_name>Bupivacaine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
    <arm_group_label>Bupivacaine (BUP)</arm_group_label>
    <arm_group_label>Chloroprocaine (CP)</arm_group_label>
    <other_name>Sublimaze</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
    <arm_group_label>Bupivacaine (BUP)</arm_group_label>
    <other_name>Salt water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I and II women

          -  18-45 yrs old

          -  Singleton pregnancy

          -  Cervical cerclage 1st or 2nd trimester of pregnancy undergoing with spinal anesthesia

          -  Height 150 - 180 cm

          -  BMI ≤ 40 kg/m2.

        Exclusion Criteria:

          -  Any contraindication to neuraxial anesthesia (history of neurologic disease (e.g.,
             multiple sclerosis, spinal stenosis, central or peripheral neuropathy)

          -  Pre-existing/chronic back pain

          -  Ester local anesthetic allergy, PABA allergy

          -  History of atypical cholinesterase (CP is metabolized by cholinesterase)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Smiley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Camponovo C, Wulf H, Ghisi D, Fanelli A, Riva T, Cristina D, Vassiliou T, Leschka K, Fanelli G. Intrathecal 1% 2-chloroprocaine vs. 0.5% bupivacaine in ambulatory surgery: a prospective, observer-blinded, randomised, controlled trial. Acta Anaesthesiol Scand. 2014 May;58(5):560-6. doi: 10.1111/aas.12291. Epub 2014 Mar 6.</citation>
    <PMID>24601887</PMID>
  </reference>
  <reference>
    <citation>Hejtmanek MR, Pollock JE. Chloroprocaine for spinal anesthesia: a retrospective analysis. Acta Anaesthesiol Scand. 2011 Mar;55(3):267-72. doi: 10.1111/j.1399-6576.2010.02371.x.</citation>
    <PMID>21288208</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <results_first_submitted>May 7, 2020</results_first_submitted>
  <results_first_submitted_qc>May 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 26, 2020</results_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Richard M. Smiley</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Chloroprocaine</keyword>
  <keyword>cervical cerclage</keyword>
  <keyword>spinal anesthesia</keyword>
  <keyword>Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Incompetence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Chloroprocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02862912/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02862912/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chloroprocaine (CP)</title>
          <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine (BUP)</title>
          <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chloroprocaine (CP)</title>
          <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine (BUP)</title>
          <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="4"/>
                    <measurement group_id="B2" value="34" spread="6"/>
                    <measurement group_id="B3" value="33" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Resolution of Motor Block</title>
        <description>The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale:
Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)</description>
        <time_frame>3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine (CP)</title>
            <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine (BUP)</title>
            <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Motor Block</title>
          <description>The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale:
Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" spread="40"/>
                    <measurement group_id="O2" value="132" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ambulate</title>
        <description>Time from spinal anesthesia placement to ability to ambulate.</description>
        <time_frame>5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine (CP)</title>
            <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine (BUP)</title>
            <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulate</title>
          <description>Time from spinal anesthesia placement to ability to ambulate.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" spread="35"/>
                    <measurement group_id="O2" value="258" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Void</title>
        <description>Time from spinal anesthesia injection to ability to void spontaneously.</description>
        <time_frame>5 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No adverse events occurred when followed up on postoperative day 1</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chloroprocaine (CP)</title>
          <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine (BUP)</title>
          <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Allison Lee</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-6494</phone>
      <email>al3196@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

